N-hydroxy-4-{2-[5-(2-pyrrolidin-1-ylethyloxy)benzofuran-2-ylcarbonylamino]ethoxy}benzamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: N-hydroxy-4-{2-[5-(2-pyrrolidin-1-ylethyloxy)benzofuran-2-ylcarbonylamino]ethoxy}benzamide
• 英文别名: N-[2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-5-(2-pyrrolidin-1-ylethoxy)-1-benzofuran-2-carboxamide
• 化学式: C₂₄H₂₇N₃O₆
• 分子量: 453.495
• InChiKey: RVUPSYZQQBAERY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-{2-[5-(2-pyrrolidin-1-ylethoxy)benzofuran-2-carbonylamino]ethoxy}benzoic acid methyl ester 在 sodium hydroxide 、 羟胺 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 18.0h， 生成 N-hydroxy-4-{2-[5-(2-pyrrolidin-1-ylethyloxy)benzofuran-2-ylcarbonylamino]ethoxy}benzamide
  参考文献：
  名称：

  [EN] HYDROXAMATES AS THERAPEUTIC AGENTS
  [FR] NOUVEAUX HYDROXAMATES ET LEUR UTILISATION COMME AGENTS THERAPEUTIQUES

  摘要：

  公开号：

  WO2004092115A3

文献信息

• Novel hydroxamates as therapeutic agents
  申请人：Verner J. Erik

  公开号：US20050187261A1

  公开（公告）日：2005-08-25

  The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

  本发明涉及某些羟酸酰胺衍生物，其在治疗丙型肝炎方面具有用途。这些化合物也是组蛋白去乙酰化酶的抑制剂，因此在治疗与组蛋白去乙酰化酶活性相关的疾病方面也具有用途。此外，还公开了制备这些化合物的制药组合物和方法。
• NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS
  申请人：Verner Erik J.

  公开号：US20090220454A1

  公开（公告）日：2009-09-03

  The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

  本发明涉及某些羟肟酸衍生物，可用于治疗丙型肝炎。这些化合物也是组蛋白去乙酰化酶的抑制剂，因此可用于治疗与组蛋白去乙酰化酶活性相关的疾病。同时，还公开了制备这些化合物的药物组合物和过程。
• Hydroxamates as therapeutic agents
  申请人：Pharmacyclics, Inc.

  公开号：US07276612B2

  公开（公告）日：2007-10-02

  The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

  本发明涉及某些羟肟酸衍生物，可用于治疗丙型肝炎。这些化合物也是组蛋白去乙酰化酶的抑制剂，因此可用于治疗与组蛋白去乙酰化酶活性相关的疾病。此外，还公开了制备这些化合物的药物组合物和过程。
• Method of Monitoring Anti-Tumor Activity of an Hdac Inhibitor
  申请人：Bass Kathryn E.

  公开号：US20080248506A1

  公开（公告）日：2008-10-09

  The present invention relates to the method of determining the anti-tumor activity of a histone deacetylase inhibitor by measuring the phosphorylation of the histone variant H2AX or the level of cytokeratin-18 fragment aa 387-397.

  本发明涉及一种通过测量组蛋白去乙酰化酶抑制剂引起的组蛋白变异体H2AX的磷酸化或细胞角蛋白18片段aa 387-397水平来确定抗肿瘤活性的方法。
• Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
  申请人：PHARMACYCLICS, INC.

  公开号：EP2626067A1

  公开（公告）日：2013-08-14

  Provided herein are methods for using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity, methods for monitoring the decrease of cellular DNA repair activity using at least one biomarker, methods of treating cancer by using at least one histone deacetylase inhibitor to decrease cellular DNA repair activity in combination therapy, methods of combination therapy where at least one histone deacetylase inhibitor interferes with a DNA repairing mechanism involving RAD51, methods for predicting a induction time period between a first administration of at least one histone deacetylase inhibitor and a second administration of at least one other therapeutic treatment, and pharmaceutical compositions for combination therapy.

  本文提供了使用至少一种组蛋白去乙酰化酶抑制剂降低细胞DNA修复活性的方法、使用至少一种生物标志物监测细胞DNA修复活性降低的方法、通过在联合疗法中使用至少一种组蛋白去乙酰化酶抑制剂降低细胞DNA修复活性来治疗癌症的方法、至少一种组蛋白去乙酰化酶抑制剂干扰涉及 RAD51 的 DNA 修复机制的联合治疗方法，预测首次给药至少一种组蛋白去乙酰化酶抑制剂与第二次给药至少一种其他治疗方法之间的诱导时间段的方法，以及用于联合治疗的药物组合物。